

1 **High-flow nasal cannula for acute exacerbation of chronic obstructive pulmonary**
2 **disease: a Cost-utility analysis**

3
4 **Short running title: Cost-utility High-flow nasal cannula**

5
6
7
8
9 Jefferson Antonio Buendía, MD PhD¹, Diana Guerrero Patiño RN MSc. ²

10 1. Research group in Pharmacology and Toxicology "INFARTO". Department of
11 Pharmacology and Toxicology. University of Antioquia, Medellín, Colombia

12 2. Hospital Infantil Concejo de Medellín, Colombia

13

14

15

16

17 **Corresponding author:** Jefferson A. Buendía, MD, PhD, Facultad de Medicina,
18 Universidad de Antioquia, Carrera 51D #62-29, Tel: (+574) 2196046; Medellín, Colombia.
19 E-mail: jefferson.buendia@gmail.com. E-mail: JAB: jefferson.buendia@gmail.com.

20 Financial disclosures: This study was supported by own funding of authors

21 Acknowledgments: None

22 Word count : 2306 words

23

24

25

26

27

28

29 **Abstract**

30 **Background:** High-flow nasal cannula (HFNC) is an alternative for delivering respiratory
31 support to adults with acute exacerbations of chronic obstructive pulmonary disease.
32 Despite increased popularity for respiratory support, there is still uncertainty about if their
33 costs of justify the clinical benefits provided. This study aims to evaluate the cost-utility of
34 HFNC in acute exacerbations of chronic obstructive pulmonary disease in Colombia

35 **Methods:** Using a decision tree model, we estimated the cost and quality-adjusted life-
36 years (QALYs) associated with HFNC and conventional oxygen therapy (COT) in adults
37 who presented to the emergency department with acute exacerbations of chronic
38 obstructive pulmonary disease. All parameters for the model were derived from published
39 research with local data. All analyses were done from a societal perspective.

40 **Results:** We estimate a gain of 0,49 and 0,48 QALYs per patient-year on HFNC and COT
41 respectively, and a difference of US\$314 in total discounted cost per person-year on HFNC
42 respecting COT. Because HFNC was associated with lower costs compared to conventional
43 therapy, the incremental cost effectiveness ratio was not calculated.

44 **Conclusions:** HFNC achieving better outcomes at a lower cost in patients with acute
45 exacerbations of chronic obstructive pulmonary disease in Colombia. Evidence should
46 continue to be generated with real-life effectiveness data and economic evaluations in other
47 countries to confirm our findings.

48 **Keywords:** health economics, public health, healthcare, oxygen, cannula

49

50 **Introduction**

51 Chronic obstructive pulmonary disease (COPD) is among the leading causes of
52 morbimortality worldwide. COPD ranked eighth among the top 20 conditions causing
53 disability globally(1). In 2015, 3.2 million people died from COPD worldwide, with an
54 increasing trend over the last 20 years (2). Acute exacerbation of COPD is the main cause
55 of death in these patients. Oxygen therapy with low-flow oxygen is initially the main
56 treatment method for patients with acute exacerbation (3). However, CO₂ retention appears
57 as acute exacerbation progresses. This hypercapnia can complicate both COPD
58 exacerbations and stable COPD (4). In some patients, this hypercapnia, with the resulting
59 hypoxia, is difficult to correct, and non-invasive positive-pressure ventilation (NIPPV) has
60 been proposed as the first mode of ventilation in acute respiratory failure and type II
61 respiratory failure (5). NIPPV has been demonstrated its effectiveness to provide
62 respiratory support in cardiogenic pulmonary edema or acute exacerbations of COPD (6).
63 However, NIPPV prevents mobilization and oral nutrition, being poorly tolerated (7, 8).
64 The failure of these devices to give correct respiratory support often results in the need for
65 intubation and mechanical ventilation.

66 HFNC, which has been used in the neonatal setting, is a relatively new method of
67 delivering respiratory support to adults with acute respiratory failure. With this device, a
68 flow of up to 60 liters per minute of warmed and humidified oxygen can be delivered with
69 few adverse reactions(9). HFNC does not need to be removed when patients talk, eat,
70 resulting in fewer interruptions of therapy. HFNC has been associated with flushing of
71 anatomical dead space due to high gas flow, generation of positive airway pressure, which
72 increases functional residual capacity and improves alveolar recruitment, ability to deliver

73 optimal humidification, leading to enhanced mucociliary transport (10). These favorable
74 physiological effects have been reflected in the metaanalysis of randomized clinical trials,
75 with significantly lower rates of treatment failure compared and with few severe adverse
76 events or safety issues (11). Using HFNC for COPD patients can reduce the frequency of
77 exacerbations and improve exercise capacity and quality of life (12, 13).

78 A recent metaanalysis of 6 randomized controlled trials with a total of 526 COPD patients
79 shows that compared with NIPPV, HFNC can reduce the PaCO₂ level, length of hospital
80 stay, and the incidence of nasal facial skin breakdown (14). Despite increased popularity as
81 a treatment modality for respiratory support, there is still uncertainty about if the additional
82 costs of this device justify the clinical benefits provided. In a previous paper, we
83 demonstrated the cost-utility of this treatment in other diseases such as acute bronchiolitis
84 with a favorable budgetary impact on the Colombian health system (15, 16). This would be
85 significant, especially for hospitals in middle-income countries with scarce health
86 resources, and where this technology could be a cost-saving alternative (17). This study
87 aims to evaluate the cost-effectiveness of HFNC in critically ill adults with hypoxemic
88 respiratory failure.

89

90

91

92

93

94

95 **Methods**

96 **Model structure**

97 Using a decision tree analysis, we estimate the cost and quality-adjusted life-years
98 (QALYs) associated with HFNC and conventional oxygen therapy (COT) in adults who
99 presented to the emergency department acute exacerbations of chronic obstructive
100 pulmonary disease (AECOPD), **figure 1**.

101 The case base, and according to the inclusion and exclusion criteria of the randomized
102 controlled trial (RCT) from which the relative risk was extracted for this mathematical
103 model, and which will be detailed below, included patients with compensated hypercapnic
104 respiratory failure, and who were aged 40 years or older (18). In this RCT compensated
105 hypercapnic respiratory failure was defined as “the baseline arterial blood gas analysis
106 (measured with room air in the supine position after at least 30 min of rest) results of pH \geq
107 7.35, partial arterial oxygen pressure (PaO₂) < 60 mmHg, and PaCO₂ > 45 mmHg” (18). In
108 our case base were excluded “patients with long-term NIPPV at home, respiratory failure
109 requiring mechanical ventilation at admittance, isolated cardiogenic pulmonary edema
110 indicating NIV, gastrointestinal hemorrhage, pneumothorax, or life-threatening organ
111 dysfunction”(18). In this trial the HFNC group utilized as respiratory support high-flow
112 devices (AIRVOTM 2; Fisher & Paykel Healthcare) and “the sizes of the nasal cannulas
113 were chosen based on patients’ nostrils, the humidifier temperature was set to 31°C, 34°C,
114 or 37°C according to the comfort degree of the patients, and the fraction of inspired oxygen
115 (FiO₂) was adjusted to maintain oxygen saturation by pulse oximetry (SpO₂) at 90% to

116 93%”. The maximum flow rate also had to be adjusted according to the patients’ maximum
117 tolerance. Patients were instructed to use HFNC for at least 15 h per day, and the total
118 treatment time had to be no less than 5 d” (18). The group with COT receives “oxygen via
119 nasal prongs for at least 15 h per day. Oxygen flow was set to achieve SpO₂ at 90% to
120 93%” (18).

121 In our decision tree analysis, we defined the following outcomes according to the natural
122 history of the disease: death, admission to PICU with a need for invasive or non-invasive
123 mechanical ventilation, admission to PICU without need for invasive or non-invasive
124 mechanical ventilation, hospitalization with the need of escalation therapy, hospitalization
125 without the need of escalation therapy. In this analytical model, any patient who presents to
126 the emergency department with an acute exacerbation of COPD after receiving oxygen with
127 HFNC or COT may or may not have a requirement to escalate the therapy to invasive
128 mechanical ventilation and after it may die or survive. In case of not requiring non-invasive
129 mechanical ventilation (state of non-escalation of therapy) , or also in the patient who
130 survives after the requirement of mechanical ventilation, it is assumed that the patient does
131 not have any sequelae and is discharged from the hospital , **figure 1**.

132 The analytic horizon was an acute episode of hypoxemic respiratory failure approximately
133 12 days (18). Given the short time horizon, no type of discount to costs or results was
134 applied. Treatment was considered cost-effective if the incremental cost-utility ratio was
135 below \$5180 per QALY gained using the willingness to pay (WTP) for QALY in
136 Colombia (19).

137 **Parameters of the model**

138 All parameters for the model were derived from published research with local data, **table 1**.
139 The relative risk of escalation of therapy and invasive mechanical ventilation of HFNC, as
140 well the transition probabilities were derived from a prospective, randomized, controlled
141 trial. In this RTC, 320 patients with AECOPD and compensated hypercapnic respiratory
142 failure were recruited from general wards in a multicentric study(18). They were
143 randomized to HFNC (with a FiO₂ adjusted to obtain an oxygen saturation at 90% to 93%
144 and with a maximum flow rate adjusted according to the patient's tolerance) for at least 15
145 h per day, and the total treatment time had to be no less than 5 days) or conventional
146 oxygen therapy or COT (oxygen delivered via nasal prongs for at least 15 h per day with a
147 flow set to achieve SpO₂ at 90% to 93%). Utilities were extracted from a prospective
148 cohort study of 195 survivors of acute respiratory distress (20). We assumed that the
149 lifetime QALYs were the same for all survivors, irrespective of whether they were in COT
150 or HFNC (21).

151 All analyses were done from a societal perspective (including direct and indirect costs). All
152 direct medical costs were incorporated into the model using the micro-costing including
153 consultation at the emergency room, specialist referrals, chest physiotherapy, diagnosis
154 support (laboratory, electrocardiogram, x-ray, etc.), oxygen (HFNC, invasive mechanical
155 ventilation, COT, NIPPV) medication (corticosteroids, bronchodilators, etc.), medical
156 devices, hotel services in the intensive care unit, hotel services and overhead cost in the
157 general medical ward. All costs were extracted from National Drug Price Information
158 System (SISMED, 2020), National Health Reference Price List (SOAT 2010), and local
159 publications (22, 23). For the valuation of the indirect costs associated with parents' loss of
160 productivity, the human capital method was used, assuming everyone receives an income of

161 at least the legal minimum wage for formal or informal work. The cost-opportunity of the
162 productivity loss at the workplace and the caregiver was assessed based on the minimum
163 wage without including transportation assistance for 2020 (US\$230 per month) (24). We
164 used US dollars (Currency rate: US\$1.00 = COP\$ 3,600) to express all costs in the
165 study(25). The incremental cost-utility ratio (ICUR) was calculated using the following
166 formulae:

$$ICUR = \frac{\text{Expected annual cost per patient with HFNC} - \text{Expected annual cost per patient without HFNC}}{\text{QALY per patient with HFNC} - \text{QALY per patient without HFNC}}$$

167

168 Also, we estimated the net monetary benefit (NMB). NMB represents the value of an
169 intervention in monetary terms(26). NMB is calculated as (incremental benefit x threshold)
170 – incremental cost. Incremental NMB measures the difference in NMB between alternative
171 interventions, a positive incremental NMB indicating that the intervention is cost-effective
172 compared with the alternative at the given willingness-to-pay threshold

173 **Sensitivity analysis**

174 All data were subjected to probabilistic sensitivity analysis as detailed below, and as
175 recommended by Consolidated Health Economic Evaluation Reporting Standards
176 (CHEERS) Statement (27). To explore parameter uncertainty of the model inputs, first, we
177 conducted a one-way sensitivity analysis represented in a tornado diagram. In this
178 deterministic analysis, to build the range of RR to be used in this analysis, we use the CI
179 95% of RR mentioned before. In the case of utilities, transition probabilities, and treatment
180 adherence, the upper and lower ranges were estimated by adding or subtracting 25% of the
181 value from the central value defined for the base case. Then, we performed probabilistic

182 sensitivity analysis by randomly sampling from each of the parameter distributions (beta-
183 distribution in the case of transition probabilities, and gamma distribution in the case of
184 costs, lognormal for length of stay, utilities, and relative risk). The expected costs and
185 expected QALYs for each treatment strategy were calculated using that combination of
186 parameter values in the model. This process was replicated one thousand times (i.e.,
187 second-order Monte Carlo simulation) for each treatment option resulting in the expected
188 cost-utility. We combined a non-parametric bootstrap-based estimation of uncertainty
189 intervals (UI 95%) and probabilistic sensitivity analysis, by drawing a vector of values from
190 normal distributions representing the parameter uncertainties of the cost parameters,
191 alongside 1'000 bootstrap replications(28). All analyses were done in TreeAge Pro 2021 ®.

192 **Results**

193 **Case-based analysis**

194 Base-case analyses showed that HFNC was associated with lower costs and higher QALYs
195 than COT. The QALYs per person estimated in the model was 0,49 (UI 95% 0,41-0,50)
196 and 0,48 (UI 95% 0,47-0,52) QALYs per patient-year on HFNC and COT, respectively.
197 The total costs per person were US\$ 965 (UI 95% 961-989) for HFNC and US\$ 1271 (UI
198 95% 1262-1298) for COT, **table 2**. A position of dominance eliminated the need to
199 calculate an incremental cost-utility ratio. The incremental NMB of corticosteroids plus
200 antibiotics over without corticosteroids was of US\$375 (CI 95% 360-396).

201 In the deterministic sensitivity analysis, our base-case results were robust to variations in all
202 assumptions and parameters except for the relative risk of HFNC, **figure 2**. If the relative
203 risk is higher than 0,86 the ICER of HFNC would exceed the WTP of US\$ 5 180, **figure 3**.

204 The results of the probabilistic sensitivity analysis are graphically represented in the cost-
205 effectiveness plane, **figure 4**. This scatter plot shows that HFNC tends to be associated with
206 higher costs and higher QALY. Indeed, for HFNC 86 % of ICER simulations were graphed
207 in quadrant 2 (lower cost, high QALYs), 5% in quadrant 1 (high cost, high QALYs). The
208 cost-effectiveness acceptability curve shows that HFNC becomes cost-effective at 100% for
209 all willingness-to-pay thresholds, **figure 5**.

210 **Discussion**

211 Our economic analysis showed that compared with oxygen therapy by nasal catheter,
212 HFNC, achieving better outcomes at a lower cost in AECOPD patients with acute
213 compensated hypercapnic respiratory failure. The difference in the cost per patient between
214 these treatments is not negligible (US\$314 per patient) even more so if we consider the
215 frequency of this disease in the population. Health economic evaluations allow translation
216 of clinical benefits, obtained from controlled clinical trials, into composite measures of cost
217 adjusted for quality of life-adjusted benefit units. In this case, HFNC allows for significant
218 savings per patient, including a favorable difference regarding quality-adjusted life years.
219 This type of evidence, although it should be replicated in other countries, allows
220 policymakers to encourage using HFNC technologies in the clinical setting.

221 Our results are in line with previous evidence. In adults, with identifying a cost-
222 effectiveness study of long-term domiciliary HFNC treatment in COPD patients with
223 chronic respiratory failure(29). This study was done on 200 COPD patients randomized
224 into usual care plus or without HFNC in the UK. The authors found an ICER of £3605 per
225 QALY gained, a value below WTP in the UK (29). Turner et al, in an economic evaluation

226 of using HFNC in intensive care units in NHS England, show that HFNC generates a cost-
227 saving of £469 per patient compared with standard oxygen and £611 versus NIV (30).
228 HFNC was found to dominate against standard oxygen and NIV when used in patients who
229 had not previously been intubated and also when compared against standard oxygen in
230 patients at low risk of re-intubation. We in a previous study estimated the cost-effectiveness
231 of HFNC compared with oxygen by nasal cannula (control strategy) in an infant with
232 bronchiolitis in the emergency setting(16). The cost per patient was US\$368 (95% CI, US\$
233 323–411) in HFNC and US\$441 (95% CI US\$ 384–498) per patient in the control group.
234 Also, we demonstrate in analysis the 5-year costs that high-flow nasal cannula was
235 associated with savings for Colombian National Health equal to US\$13,166,071 if the high-
236 flow nasal cannula was adopted for the routine management of patients with acute
237 bronchiolitis(15).

238 Our findings are in line with the effectiveness of HFNC reported by a recent meta-analysis.
239 HFNC, respect to NIPPV in patients with COPD and type II respiratory failure,
240 significantly reduce PaCO₂ level (MD = - 2,64 95% CI (- 3,12 to - 2,15)), length of
241 hospital stay ((MD = - 1,19 , 95 CI (- 2,23 to - 0,05)) with a incidence of nasal facial skin
242 breakdown ((OR = 0,11, 95% CI (0,03–0,41))(14). In patients with COPD with persistent
243 hypercapnic and hypoxic failures, a domiciliary high-flow nasal cannula (HFNC) prevents
244 progression in hypercapnia, the number of exacerbations, and hospitalizations (31). In this
245 RTC 200 patients with advanced COPD and persistent hypoxic were randomized to usual
246 care or usual care plus HFNC for 12 months. After 12 months there was a 1,3% decrease in
247 PaCO₂ in patients using HFNC and a 7% increase in controls before HFNC (p=0.003). The
248 exacerbation rate increased, compared with 12 months; pre-study, was by 2.2/year for

249 controls ($p < 0.001$) and 0,15/ year for HFNC-treated patients ($p = 0.661$). Hospital admission
250 rates increased in the control group, +0,3/year ($p = 0.180$), while decreasing by 0,67/year
251 ($p = 0.013$) for HFNC-treated patients (31). Although the evidence is still controversial
252 insofar as there are also studies where such beneficial effects are not seen, especially in
253 variables such as PCO₂ and PO₂ (32, 33), our study contributes to this knowledge by
254 providing evidence that HFNC is cost-effective in resource-limited populations beyond
255 intermediate discharges, given that such technology impacts the risk of escalation of
256 therapy to more invasive and more expensive ventilation systems.

257 A very important aspect of our model is that it was robust to changing the model's utility
258 and cost values. HFNC was always the most cost-effective strategy in all ranges of cost and
259 utilities evaluated. Although our utilities were collected from other populations, our results
260 did not change when exploring the change in the ICER in the range of values of each utility
261 explored. These aspects give us confidence concerning the ability to make decisions based
262 on our results. As is always necessary for science, more studies are needed to replicate our
263 results (34).

264 Our study has some limitations. As we mentioned before, we use utilities, transition
265 probabilities, and relative risk extracted from the literature and not estimated directly from
266 our population. As was mentioned previously, the reliability and robustness of the results
267 were evaluated using sensitivity analysis. An additional strength is the perspective of the
268 society on which the economic analysis was focused, which allows a faster transfer of
269 results to health policies.

270 In conclusion, HFNC achieving better outcomes at a lower cost in patients with acute
271 exacerbations of chronic obstructive pulmonary disease. Evidence should continue to be
272 generated with real-life effectiveness data and economic evaluations in other countries to
273 confirm our findings.

274

275

276 **References**

- 277 1. Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause
278 mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis
279 for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1459-544.
- 280 2. Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-
281 adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and
282 asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*
283 *Respir Med*. 2017;5(9):691-706.
- 284 3. Duffy SP, Criner GJ. Chronic Obstructive Pulmonary Disease: Evaluation and Management.
285 *Med Clin North Am*. 2019;103(3):453-61.
- 286 4. Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute
287 exacerbations of COPD. *QJM*. 2010;103(11):817-29.
- 288 5. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global Initiative for
289 the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD
290 Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. *Am J Respir*
291 *Crit Care Med*. 2021;203(1):24-36.
- 292 6. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. *Lancet*.
293 2009;374(9685):250-9.
- 294 7. Bello G, De Pascale G, Antonelli M. Noninvasive Ventilation. *Clin Chest Med*.
295 2016;37(4):711-21.
- 296 8. Gregoretto C, Confalonieri M, Navalesi P, Squadrone V, Frigerio P, Beltrame F, et al.
297 Evaluation of patient skin breakdown and comfort with a new face mask for non-invasive
298 ventilation: a multi-center study. *Intensive Care Med*. 2002;28(3):278-84.
- 299 9. Nishimura M. High-flow nasal cannula oxygen therapy in adults. *J Intensive Care*.
300 2015;3(1):15.
- 301 10. Lodeserto FJ, Lettich TM, Rezaie SR. High-flow Nasal Cannula: Mechanisms of Action and
302 Adult and Pediatric Indications. *Cureus*. 2018;10(11):e3639.
- 303 11. Corley A, Rickard CM, Aitken LM, Johnston A, Barnett A, Fraser JF, et al. High-flow nasal
304 cannulae for respiratory support in adult intensive care patients. *Cochrane Database Syst Rev*.
305 2017;5:CD010172.
- 306 12. Pisani L, Astuto M, Prediletto I, Longhini F. High flow through nasal cannula in exacerbated
307 COPD patients: a systematic review. *Pulmonology*. 2019;25(6):348-54.

- 308 13. Bruni A, Garofalo E, Cammarota G, Murabito P, Astuto M, Navalesi P, et al. High Flow
309 Through Nasal Cannula in Stable and Exacerbated Chronic Obstructive Pulmonary Disease Patients.
310 Rev Recent Clin Trials. 2019;14(4):247-60.
- 311 14. Xu Z, Zhu L, Zhan J, Liu L. The efficacy and safety of high-flow nasal cannula therapy in
312 patients with COPD and type II respiratory failure: a meta-analysis and systematic review. Eur J
313 Med Res. 2021;26(1):122.
- 314 15. Buendia JA, Acuna-Cordero R, Rodriguez-Martinez CE. Budget impact analysis of high-flow
315 nasal cannula for infant bronchiolitis: the Colombian National Health System perspective. Curr
316 Med Res Opin. 2021;37(9):1627-32.
- 317 16. Buendia JA, Acuna-Cordero R, Rodriguez-Martinez CE. The cost-utility of early use of high-
318 flow nasal cannula in bronchiolitis. Health Econ Rev. 2021;11(1):41.
- 319 17. Slain KN, Shein SL, Rotta AT. The use of high-flow nasal cannula in the pediatric emergency
320 department. J Pediatr (Rio J). 2017;93 Suppl 1:36-45.
- 321 18. Li XY, Tang X, Wang R, Yuan X, Zhao Y, Wang L, et al. High-Flow Nasal Cannula for Chronic
322 Obstructive Pulmonary Disease with Acute Compensated Hypercapnic Respiratory Failure: A
323 Randomized, Controlled Trial. Int J Chron Obstruct Pulmon Dis. 2020;15:3051-61.
- 324 19. Espinosa O, Rodriguez-Lesmes P, Orozco E, Avila D, Enriquez H, Romano G, et al.
325 Estimating Cost-Effectiveness Thresholds Under a Managed Healthcare System: Experiences from
326 Colombia. Health Policy Plan. 2021.
- 327 20. Ferguson ND, Scales DC, Pinto R, Wilcox ME, Cook DJ, Guyatt GH, et al. Integrating
328 mortality and morbidity outcomes: using quality-adjusted life years in critical care trials. Am J
329 Respir Crit Care Med. 2013;187(3):256-61.
- 330 21. Thokala P, Goodacre S, Ward M, Penn-Ashman J, Perkins GD. Cost-effectiveness of Out-of-
331 Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure. Ann Emerg Med.
332 2015;65(5):556-63 e6.
- 333 22. Ministerio de salud C. Sistema de Informacion de Precios de Medicamentos (SISMED) 2021
334 [03/07/2121]. Available from: [www.sispro.gov.co/central-prestadores-de-servicios/Pages/SISMED-
335 Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx](http://www.sispro.gov.co/central-prestadores-de-servicios/Pages/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx).
- 336 23. Enciso Oliviera C., Guerra Urrego KA, Duque M., E. MG. Costos de Atencion en UCI de un
337 Hospital Universitario de Bogota. Repertorio de Medicina y Cirugia 2006;15(3).
- 338 24. (DANE) DNdE. Archivo nacional de datos 2019 [Available from:
339 <https://sitios.dane.gov.co/anda-index/>. .
- 340 25. Estadísticas DAN. Índice de Precios al Consumidor - IPC 2020 [Available from:
341 [https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-
342 consumidor-ipc](https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc)
- 343 26. Consortium YHE. Net Monetary Benefit [online] 2016 [Available from:
344 <https://yhec.co.uk/glossary/net-monetary-benefit/>.
- 345 27. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.
346 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health.
347 2013;16(2):e1-5.
- 348 28. Lord J, Asante MA. Estimating uncertainty ranges for costs by the bootstrap procedure
349 combined with probabilistic sensitivity analysis. Health Econ. 1999;8(4):323-33.
- 350 29. Sorensen SS, Storgaard LH, Weinreich UM. Cost-Effectiveness of Domiciliary High Flow
351 Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure. Clinicoecon Outcomes
352 Res. 2021;13:553-64.
- 353 30. Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen
354 through nasal cannula in intensive care units in NHS England. Expert Rev Pharmacoecon Outcomes
355 Res. 2018;18(3):331-7.

- 356 31. Storgaard LH, Hockey HU, Weinreich UM. Development in PaCO₂ over 12 months in
357 patients with COPD with persistent hypercapnic respiratory failure treated with high-flow nasal
358 cannula-post-hoc analysis from a randomised controlled trial. *BMJ Open Respir Res.* 2020;7(1).
359 32. Huang X, Du Y, Ma Z, Zhang H, Jun L, Wang Z, et al. High-flow nasal cannula oxygen versus
360 conventional oxygen for hypercapnic chronic obstructive pulmonary disease: A meta-analysis of
361 randomized controlled trials. *Clin Respir J.* 2021;15(4):437-44.
362 33. Pisani L, Betti S, Biglia C, Fasano L, Catalanotti V, Prediletto I, et al. Effects of high-flow
363 nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a
364 prospective pilot study. *BMC Pulm Med.* 2020;20(1):12.
365 34. Buendia JA. [Attitudes, knowledge and beliefs of patient about anti-hypertensive drugs].
366 *Biomedica.* 2012;32(4):578-84.

367

368

369 **Figure legends**

370 **Figure 1.** Decision tree model

371 **Figure 2.** Tornado diagram

372 **Figure 3.** Threshold analysis of relative risk of escalation therapy of HFNC vs
373 Conventional oxygen therapy

374 **Figure 4.** Cost effectiveness plane

375 **Figure 5.** Acceptability curve

376

377

378

379

380

381

382

383

384

385

386

387

388

389 **Table 1.** Case Base

Variable	Base case	High Value	Low Value	Ref
Cost US\$ (per /patient day)				
High-flow nasal cannula	58	72	43	
Escalation therapy state with need of invasive or non-invasive mechanical ventilation	495	618	371	(23,23)
Escalation therapy state without need of invasive or non-invasive mechanical ventilation	425	566	339	
Non-escalation state	28	33	20	
Utilities				
Acute respiratory failure	0,5	0,62	0,37	(20)
Relative risk on probability of escalation therapy	0,54	0,29	0,91	(18)
Relative risk on probability of invasive or non-invasive mechanical ventilation	0,52	0,27	0,94	
Transition probabilities				
Probability of escalation therapy with conventional oxygen therapy	0,19	0,4	0,24	
Probability of invasive or non-invasive mechanical ventilation in escalation therapy	0,16	0,36	0,22	
Probability of death in patients with need of invasive or non-invasive mechanical ventilation	0,27	0,34	0,20	(18)

390

391

392

393

394

395

396

397

398

399

400

401

402

403 **Table 2.** Cost effectiveness analysis

Strategy	Cost per patient (US\$)	Difference (US\$)	QUALYs	Difference	NMB(US\$)	ICUR
HFNC	674		0,49		8787	
COT	988	-314	0,48	0,01	8412	(Dominated)

404

405 NMB: Net monetary benefit

406 ICUR : Incremental cost-utility ratio

407 COT : conventional oxygen therapy

408 HFNC : High flow nasal cannula

409

410

411

412

413

414

415

416

417

418

419

420 **Figure 1.** Decision tree model

421 **Figure 2.** Tornado diagram

422 **Figure 3.** Threshold analysis of relative risk of escalation therapy of HFNC vs
423 Conventional oxygen therapy

424 **Figure 4.** Cost effectiveness plane

425 **Figure 5.** Acceptability Curve

426

Figure 5. Acceptability Curve




Figure 4. Cost effectiveness plane




Figure 3. Threshold analysis of relative risk of escalation therapy of HFNC vs Conventional oxygen therapy




Figure 2. Tornado diagram




Figure 1. Decision tree model

